RVPH: Preliminary OLE Readout
Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...
229 Views
MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial
On December 18, 2024, MetaVia announced positive topline results from the Phase 2a clinical trial of DA-1241 in patients with presumed metabolic...
403 Views
MIRA: IND Application Submitted to FDA
MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
416 Views
MIRA: IND Application Submitted to FDA
MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
346 Views
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway
On December 16, 2024, Soligenix, Inc. (SNGX) announced it has opened patient enrollment for the confirmatory Phase 3 FLASH2 (Fluorescent Light...
239 Views